Abstract: Expert analysis reveals that outcomes in lung cancer treatment involving novel drugs depend less on the drugs themselves and more on systemic changes in disease management. These outcomes are tied to key acceptability factors: patient awareness and perceptions regarding early diagnosis and adherence, awareness and qualifications of healthcare providers (HCPs), and overall affordability and availability. Consequently, a rational model for disease control must consider medical technology as a multi-agent integrated system. This complex must include both the medical intervention (the drug) and the critical accessibility factors that ensure treatment success, ultimately transforming the underlying healthcare infrastructure, financing, and specialist expertise.